当前位置: 首页 >> 检索结果
共有 20122 条符合本次的查询结果, 用时 2.087127 秒

1101. Why is progressive ILD in systemic sclerosis so difficult to predict?

作者: Kathleen Morrisroe.;Murray Barron.
来源: Lancet Rheumatol. 2025年7卷7期e452-e453页

1102. Performance of the Large Language Models in African rheumatology: a diagnostic test accuracy study of ChatGPT-4, Gemini, Copilot, and Claude artificial intelligence.

作者: Yannick Laurent Tchenadoyo Bayala.;Wendlassida Joelle Stéphanie Zabsonré/Tiendrebeogo.;Dieu-Donné Ouedraogo.;Fulgence Kaboré.;Charles Sougué.;Aristide Relwendé Yameogo.;Wendlassida Martin Nacanabo.;Ismael Ayouba Tinni.;Aboubakar Ouedraogo.;Yamyellé Enselme Zongo.
来源: BMC Rheumatol. 2025年9卷1期54页
Artificial intelligence (AI) tools, particularly Large Language Models (LLMs), are revolutionizing medical practice, including rheumatology. However, their diagnostic capabilities remain underexplored in the African context. To assess the diagnostic accuracy of ChatGPT-4, Gemini, Copilot, and Claude AI in rheumatology within an African population.

1103. How JAK inhibitors tip the prothrombotic balance in rheumatoid arthritis.

作者: Vibeke Strand.
来源: Nat Rev Rheumatol. 2025年21卷8期443-444页

1104. Vascular Ehlers-Danlos syndrome: a heritable condition with potentially fatal consequences.

作者: Emily Woods.;Jessica M Bowen.;Diana S Johnson.;Glenda J Sobey.
来源: Lancet Rheumatol. 2025年

1105. The use of IL-1 and IL-6 inhibitors should be prioritised in Still's disease.

作者: Stéphane Mitrovic.;Rashmi Sinha.;Fabrizio De Benedetti.;Bruno Fautrel.
来源: Lancet Rheumatol. 2025年7卷7期e459-e460页

1106. The use of IL-1 and IL-6 inhibitors should be prioritised in Still's disease - Authors' reply.

作者: Yujie Shen.;Jinchao Jia.;Jialin Teng.;Chengde Yang.;Qiongyi Hu.
来源: Lancet Rheumatol. 2025年7卷7期e460-e461页

1107. Camptodactyly-arthropathy-coxa vara-pericarditis syndrome: a hidden culprit behind joint limitation.

作者: Hilmi Berkan Abacıoğlu.;Ahmet Furkan Çolak.;Berkay Yalçınkaya.;Alp Çetin.
来源: Rheumatology (Oxford). 2025年64卷9期5198页

1108. Single-cell transcriptome analysis profiles cellular and molecular alterations in aortic tissue from patients with Behçet's syndrome.

作者: Cong Wang.;Taotao Li.;Junmin Zhu.;Bokang Qiao.;Zhiyu Qiao.;Haiou Hu.;Nan Zhang.;Hai Yu.;Honglei Zhao.;Yongliang Zhong.;Lili Pan.;Na Gao.
来源: Rheumatology (Oxford). 2025年64卷9期5037-5047页
This study aims to analyse the expression profiles, phenotypes, functions and cell-cell communication of various cell subpopulations in the affected aortic tissues of patients with Behçet's syndrome (BS) at the transcriptomic level.

1109. Effect of rituximab on long-term damage acquisition in patients with systemic lupus erythematosus.

作者: Amanda da Silva Brito.;Sofia Miranda.;Teresa Moitinho de Almeida.;David A Isenberg.
来源: Rheumatology (Oxford). 2025年64卷9期5031-5036页
B-cell depletion therapy has been used for over two decades to treat SLE, but there is a lack of studies reporting its impact on damage progression. This study aims to assess the effectiveness of rituximab in slowing damage acquisition.

1110. Targeting interferon responses in juvenile dermatomyositis: Siglec-1 as an in vitro biomarker for JAK inhibitor efficacy.

作者: Saskia R Veldkamp.;Maud Reugebrink.;Sanne W Evers.;Thomas R J Moreau.;Vincent Bondet.;Wineke Armbrust.;J Merlijn van den Berg.;Petra C E Hissink Muller.;Sylvia Kamphuis.;Ellen Schatorjé.;Eveline M Delemarre.;Anneke J van der Kooi.;Brigitte Bader-Meunier.;Darragh Duffy.;Mathieu P Rodero.;Joost Raaphorst.;Annet van Royen-Kerkhof.;Marc H A Jansen.;Femke van Wijk.
来源: Rheumatology (Oxford). 2025年64卷9期5132-5141页
For IFN-driven diseases, such as juvenile dermatomyositis (JDM), there is a critical need for targeted therapies. We aimed to develop an in vitro model, using Siglec-1 as read-out, to evaluate inhibition of IFN-mediated responses with different JAK inhibitors (JAKi).

1111. An atypical manifestation of Giant cell arteritis (GCA): constitutional symptoms & lingual ulcer in a 78-Year-Old male with negative temporal artery biopsies.

作者: James Gow.;David Roofeh.
来源: BMC Rheumatol. 2025年9卷1期53页
Giant cell arteritis (GCA) is a large vessel vasculitis characterized by granulomatous inflammation classically affecting the carotid artery branches. GCA most often presents with one or more classic clinical features which include headache, jaw claudication, temporal scalp tenderness, and polymyalgia rheumatica. In a minority of cases, GCA can adopt an "occult" presentation (i.e., failure to thrive in the setting of unexplained inflammation) where vascular manifestations affect vascular beds, such as lingual ulceration, not amenable to biopsy. While the diagnosis of GCA is often supported by temporal artery biopsy or imaging studies, such as temporal artery ultrasound or magnetic resonance angiography, these techniques are known to have limited sensitivity. As a result, there is the potential for GCA to be misdiagnosed where it presents both in the absence of classic clinical manifestations and without clear diagnostic evidence by imaging or histopathology.

1112. Influence of socioeconomic status on access to temporal artery biopsy and rates of biopsy positivity in patients with suspected giant cell arteritis.

作者: Suellen Anne Lyne.;Susan Lester.;Oscar Kenneth Russell.;Carlee Deanne Ruediger.;Kathryn Dyer.;Jem Ninan.;Ernst Michael Shanahan.;Catherine Louise Hill.
来源: BMC Rheumatol. 2025年9卷1期52页
Data regarding the relationship between socioeconomic status (SES) and incidence of Giant Cell Arteritis (GCA) is conflicting. No previous studies have explored whether SES influences the likelihood of undergoing temporal artery biopsy (TAB). The aim of this study was to determine whether SES influences access to TAB and rate of biopsy positivity in those with suspected GCA.

1113. Fibroblasts in immune responses, inflammatory diseases and therapeutic implications.

作者: Angela E Zou.;Suppawat Kongthong.;Alisa A Mueller.;Michael B Brenner.
来源: Nat Rev Rheumatol. 2025年21卷6期336-354页
Once regarded as passive bystander cells of the tissue stroma, fibroblasts have emerged as active orchestrators of tissue homeostasis and disease. From regulating immunity and controlling tissue remodelling to governing cell growth and differentiation, fibroblasts assume myriad roles in guiding normal tissue development, maintenance and repair. By comparison, in chronic inflammatory diseases such as rheumatoid arthritis, fibroblasts recruit and sustain inflammatory leukocytes, become dominant producers of pro-inflammatory factors and catalyse tissue destruction. In other disease contexts, fibroblasts promote fibrosis and impair host control of cancer. Single-cell studies have uncovered striking transcriptional and functional heterogeneity exhibited by fibroblasts in both normal tissues and diseased tissues. In particular, advances in the understanding of fibroblast pathology in rheumatoid arthritis have shed light on pathogenic fibroblast states in other chronic diseases. The differentiation and activation of these fibroblast states is driven by diverse physical and chemical cues within the tissue microenvironment and by cell-intrinsic signalling and epigenetic mechanisms. These insights into fibroblast behaviour and regulation have illuminated therapeutic opportunities for the targeted deletion or modulation of pathogenic fibroblasts across many diseases.

1114. The pathogenesis, clinical presentations and treatment of monogenic systemic vasculitis.

作者: Ahmet Gül.;Ivona Aksentijevich.;Paul Brogan.;Marco Gattorno.;Peter C Grayson.;Seza Ozen.
来源: Nat Rev Rheumatol. 2025年21卷7期414-425页
Many monogenic autoinflammatory diseases, including DADA2 (deficiency of adenosine deaminase 2), HA20 (haploinsufficiency of A20), SAVI (STING-associated vasculopathy with onset in infancy), COPA syndrome, LAVLI (LYN kinase-associated vasculopathy and liver fibrosis) and VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, present predominantly with vasculitis and constitute a substantial subgroup of vasculitic conditions associated with a 'probable aetiology'. The spectrum of monogenic vasculitis encompasses all sizes and types of blood vessel, ranging from large vessels to medium-size and small vessels, and from the arterial side to the venous side of the vasculature. Monogenic vasculitis typically starts early in life during infancy or childhood; VEXAS syndrome, which presents in late adulthood, is an exception. The activation of myeloid cells via inflammasome and nuclear factor-κB pathways, type I interferon-enhanced autoimmune mechanisms and/or dysregulated adaptive immune responses have an important role in the development of immune-mediated endothelial dysfunction and vascular damage. Genetic testing is essential for the diagnosis of underlying monogenic autoinflammatory diseases; however, the penetrance of genetic variants can vary. Increased awareness and recognition of distinctive clinical findings could facilitate earlier diagnosis and allow for more-targeted treatments.

1115. Secukinumab is effective and safe for patients with giant cell arteritis after tocilizumab failure.

作者: Alessandro Tomelleri.;Milena Bond.;Chiara Marvisi.;Corrado Campochiaro.;Nicola Farina.;Biancamaria Venerandi.;Marco Matucci-Cerinic.;Carlo Salvarani.;Christian Dejaco.;Lorenzo Dagna.
来源: Rheumatology (Oxford). 2025年64卷9期5118-5122页
To evaluate the effectiveness and safety of secukinumab in patients with GCA who experienced an inadequate response to tocilizumab.

1116. Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from the FIRST registry.

作者: Satoshi Kubo.;Yusuke Miyazaki.;Hiroaki Tanaka.;Yuya Fujita.;Hidenori Sakai.;Masanobu Ueno.;Yasuyuki Todoroki.;Yurie Satoh-Kanda.;Ippei Miyagawa.;Shingo Nakayamada.;Yoshiya Tanaka.
来源: Rheumatology (Oxford). 2025年64卷9期5023-5030页
To elucidate the prevailing concerns by analysing the shifts in clinical profiles and therapeutic outcomes of patients with RA from 2003 to 2022, and offer guidelines to refine future treatment approaches.

1117. Pre-treatment GlycA measurement provides no additional predictive utility beyond routine clinical measures in patients with rheumatoid arthritis.

作者: Stephanie F Ling.;Chuan Fu Yap.;Nisha Nair.;Suzanne M M Verstappen.;Ann W Morgan.;John D Isaacs.;Anthony G Wilson.;Kimme L Hyrich.;Anne Barton.;Darren Plant.
来源: Rheumatology (Oxford). 2025年64卷7期4417-4419页

1118. Impact of glucocorticoid tapering speed on renal outcomes in proliferative lupus nephritis: a multicentre retrospective study.

作者: Koichiro Ohmura.;Hayato Shimizu.;Yoshiya Tanaka.;Keiju Hiromura.;Hiroki Hayashi.;Kazuro Kamada.;Kentaro Minowa.;Yutaka Kawahito.;Akiho Iwashita.;Shinya Kaname.;Shinsuke Yasuda.;Kazuoto Hiramoto.;Shoichi Maruyama.;Nobuyuki Yajima.;Yasunori Iwata.;Isao Matsumoto.;Takahisa Gono.;Hiroko Sato.;Satoshi Kubo.;Singo Nakayamada.;Hidekazu Ikeuchi.;Yukio Yuzawa.;Michihito Kono.;Naoto Tamura.;Takahiro Seno.;Takashi Kida.;Aki Sakashita.;Akira Onishi.;Akio Morinobu.;Takahisa Kawakami.;Tadashi Hosoya.;Taiki Yamaguchi.;Yuko Kaneko.;Hironari Hanaoka.;Sawako Kato.;Kayaho Maeda.;Shiori Nakagawa.;Yuya Kondo.;Masataka Kuwana.;Tomonori Ishii.;Shuji Sumitomo.;Chisato Miyakoshi.;Tatsuya Atsumi.
来源: Rheumatology (Oxford). 2025年64卷9期5014-5022页
Recent guidelines and recommendations for LN suggest rapid glucocorticoid (GC) reduction; however, robust supporting evidence remains limited. This study aimed to evaluate the impact of rapid GC reduction on renal outcomes in patients with proliferative LN.

1119. Efficacy and safety of ultrasound-guided needle muscle biopsy in the diagnosis of idiopathic inflammatory myopathies.

作者: Filipa Costa.;Raquel Campanilho-Marques.;Eduardo Dourado.;Matilde Bandeira.;Rafael Roque.;João Eurico Fonseca.;Fernando Saraiva.
来源: Rheumatology (Oxford). 2025年64卷9期5123-5131页
We aimed to assess the safety and efficacy of ultrasound-guided needle muscle biopsy (UGNMB) using a 14G biopsy needle in obtaining adequate samples for histological analysis and establishing an inflammatory idiopathic myopathy (IIM) diagnosis in patients with suspected myositis.

1120. Region-specific, data-driven guidelines are needed for rheumatic diseases in LMICs.

作者: Amita Aggarwal.
来源: Nat Rev Rheumatol. 2025年21卷8期445-446页
共有 20122 条符合本次的查询结果, 用时 2.087127 秒